How SOCS1 and PIAS1 control fibrotic skin signals (for people with scleroderma)
Official title: Antifibrotic mechanisms of SOCS1 and PIAS1 to regulate EGFR-STAT1 signaling in skin fibrosis
Funded at Yale University · NIH-11446838 · Data updated 2026-11-12
This grant seeks to understand how specific proteins control scarring in the skin of people with scleroderma, with the goal of guiding safer therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 15, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $592,338 |
| NIH project number | 1R01AR086927-01A1 |
| Project ID | NIH-11446838 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with scleroderma or related cutaneous fibrosis may potentially benefit from future therapies arising from this research.
✕Less likely to help
Individuals without fibrotic skin conditions may not directly benefit from these findings.
What this research studies
Scleroderma causes fibrosis and scarring in the skin and sometimes organs, leading to serious health problems. The project will study how STAT1 and related regulators (SOCS1 and PIAS1) influence signals that drive fibrotic gene activity in skin cells. Researchers will map molecular interactions and test how changing SOCS1/PIAS1 levels affects the EGFR-STAT1 pathway in skin fibroblasts. The aim is to identify targets that could be blocked or modulated to reduce fibrosis. Results could inform future therapies that specifically address the signaling chain involved in human skin disease.
Why it matters
Potential benefit: If successful, the work could point to new therapeutic strategies to reduce skin fibrosis in scleroderma patients.
How similar studies have gone: Previous research has linked EGFR-STAT1 signaling to fibrosis, with partial evidence that regulators like SOCS1/PIAS1 influence this pathway, suggesting potential but still early translational impact.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Odell, Ian D — Yale University
- Study coordinator: Odell, Ian D
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.